Ocular Hypertension – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ocular Hypertension – Pipeline Review, H2 2017’, provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension

The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects

The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aerie Pharmaceuticals Inc

Alcon Laboratories Inc

Allergan Plc

Bausch & Lomb Inc

Can-Fite BioPharma Ltd

D. Western Therapeutics Institute Inc

F. Hoffmann-La Roche Ltd

Ironwood Pharmaceuticals Inc

Laboratoires Thea SA

Laboratorios Sophia SA de CV

Neurim Pharmaceuticals Ltd

NicOx SA

Ocular Therapeutix Inc

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Shire Plc

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ocular Hypertension - Overview 6

Ocular Hypertension - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Ocular Hypertension - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Ocular Hypertension - Companies Involved in Therapeutics Development 23

Aerie Pharmaceuticals Inc 23

Alcon Laboratories Inc 23

Allergan Plc 24

Bausch & Lomb Inc 24

Can-Fite BioPharma Ltd 25

D. Western Therapeutics Institute Inc 25

F. Hoffmann-La Roche Ltd 26

Ironwood Pharmaceuticals Inc 26

Laboratoires Thea SA 27

Laboratorios Sophia SA de CV 27

Neurim Pharmaceuticals Ltd 28

NicOx SA 28

Ocular Therapeutix Inc 29

Santen Pharmaceutical Co Ltd 30

Senju Pharmaceutical Co Ltd 30

Shire Plc 31

Sun Pharma Advanced Research Company Ltd 31

Sylentis SAU 32

Ocular Hypertension - Drug Profiles 33

(bimatoprost + timolol) - Drug Profile 33

(latanoprost + netarsudil mesylate) - Drug Profile 34

(latanoprost + timolol maleate) - Drug Profile 39

bamosiran - Drug Profile 40

bimatoprost ocular insert - Drug Profile 43

bimatoprost SR - Drug Profile 45

brimonidine tartrate - Drug Profile 47

Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 48

H-1129 - Drug Profile 49

IWP-953 - Drug Profile 50

latanoprost - Drug Profile 51

latanoprost SR - Drug Profile 52

latanoprost SR - Drug Profile 54

latanoprost SR - Drug Profile 56

latanoprostene bunod - Drug Profile 57

MGV-354 - Drug Profile 62

NCX-1653 - Drug Profile 63

NCX-470 - Drug Profile 64

NCX-667 - Drug Profile 66

netarsudil mesylate - Drug Profile 67

omidenepag isopropyl - Drug Profile 74

piclidenoson - Drug Profile 76

piromelatine - Drug Profile 86

PRO-067 - Drug Profile 88

RO-5093151 - Drug Profile 89

sepetaprost - Drug Profile 90

SHP-639 - Drug Profile 91

SJP-0135 - Drug Profile 92

SNJ-1656 - Drug Profile 93

travoprost ER - Drug Profile 95

travoprost SR - Drug Profile 96

travoprost XR - Drug Profile 98

Ocular Hypertension - Dormant Projects 101

Ocular Hypertension - Discontinued Products 103

Ocular Hypertension - Product Development Milestones 104

Featured News & Press Releases 104

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

List of Tables

List of Tables

Number of Products under Development for Ocular Hypertension, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ocular Hypertension – Pipeline by Aerie Pharmaceuticals Inc, H2 2017

Ocular Hypertension – Pipeline by Alcon Laboratories Inc, H2 2017

Ocular Hypertension – Pipeline by Allergan Plc, H2 2017

Ocular Hypertension – Pipeline by Bausch & Lomb Inc, H2 2017

Ocular Hypertension – Pipeline by Can-Fite BioPharma Ltd, H2 2017

Ocular Hypertension – Pipeline by D. Western Therapeutics Institute Inc, H2 2017

Ocular Hypertension – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Ocular Hypertension – Pipeline by Ironwood Pharmaceuticals Inc, H2 2017

Ocular Hypertension – Pipeline by Laboratoires Thea SA, H2 2017

Ocular Hypertension – Pipeline by Laboratorios Sophia SA de CV, H2 2017

Ocular Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, H2 2017

Ocular Hypertension – Pipeline by NicOx SA, H2 2017

Ocular Hypertension – Pipeline by Ocular Therapeutix Inc, H2 2017

Ocular Hypertension – Pipeline by Santen Pharmaceutical Co Ltd, H2 2017

Ocular Hypertension – Pipeline by Senju Pharmaceutical Co Ltd, H2 2017

Ocular Hypertension – Pipeline by Shire Plc, H2 2017

Ocular Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Ocular Hypertension – Pipeline by Sylentis SAU, H2 2017

Ocular Hypertension – Dormant Projects, H2 2017

Ocular Hypertension – Dormant Projects, H2 2017 (Contd..1), H2 2017

Ocular Hypertension – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Ocular Hypertension, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports